Therapeutic Asset Ratings
534 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
skl27969
Cancer
SK Life Science, Inc.
P1/2
CC
(40)
Solnerstotug
Cancer
Sensei Biotherapeutics, Inc.
P1/2
CC
(40)
Sti-7349
Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
P1/2
CC
(40)
Stk-012
Cancer
Synthekine
P1/2
CC
(40)
Stx-001
Cancer
Strand Therapeutics Inc.
P1/2
CC
(40)
t3011
Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
P1/2
CC
(40)
t3p-y058-739
Cancer
T3 Pharmaceuticals AG
P1/2
CC
(40)
tfx05-01
Cancer
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
P1/2
CC
(40)
Tirelizumab
Cancer
LaNova Medicines Limited
P1/2
CC
(40)
tj1133
Cancer
TJ Biopharma Co., Ltd.
P1/2
CC
(40)
tqb2101 for
Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P1/2
CC
(40)
tqb2102
Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P1/2
CC
(40)
Transcon Il-2 Β/Γ
Cancer
Ascendis Pharma Oncology Division A/S
P1/2
CC
(40)
Transcon Tlr7/8 Agonist
Cancer
Ascendis Pharma Oncology Division A/S
P1/2
CC
(40)
Trastuzumab Emtansine
Cancer
Seoul National University Bundang Hospital
P1/2
CC
(40)
Ttx-Mc138
Cancer
TransCode Therapeutics
P1/2
CC
(40)
tu2218
Cancer
TiumBio Co., Ltd.
P1/2
CC
(40)
Tulmimetostat
Cancer
Novartis Pharmaceuticals
P1/2
CC
(40)
Tyra-300
Cancer
Tyra Biosciences, Inc
P1/2
CC
(40)
Urea
Cancer
Robert Bok, MD, PhD
P1/2
CC
(40)
Vls-1488
Cancer
Volastra Therapeutics, Inc.
P1/2
CC
(40)
Vofatamab
Cancer
Fusion Pharmaceuticals Inc.
P1/2
CC
(40)
wjb001
Cancer
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
P1/2
CC
(40)
xon7
Cancer
Xenothera SAS
P1/2
CC
(40)
xtx301
Cancer
Xilio Development, Inc.
P1/2
CC
(40)
Showing 201 to 225 of 534 assets
Previous
Page 9 of 22
Next
